Over the past 12 months, 10 insiders at MADRIGAL PHARMACEUTICALS, INC. filed 245 open-market SEC Form 4 transactions on MDGL: 54 purchases worth $61.9M and 191 sales worth $159.2M. Insiders have been net sellers over this period. The most recent filing was on Mar 6, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 6, 26 | Rebecca TaubDirector | SELL | 491 | $431.94 | $212K |
| Mar 6, 26 | Mardi DierEVP and CFO | SELL | 646 | $437.65 | $279K |
| Mar 6, 26 | Carole HuntsmanChief Commercial Officer | SELL | 419 | $431.94 | $181K |
| Mar 6, 26 | Shannon T KelleyGeneral Counsel | SELL | 360 | $431.94 | $155K |
| Mar 6, 26 | William John SiboldPresident and CEO | SELL | 1.7K | $431.94 | $718K |
| Mar 2, 26 | Mardi DierEVP and CFO | SELL | 1.2K | $427.21 | $505K |
| Jan 26, 26 | Carole HuntsmanChief Commercial Officer | SELL | 570 | $494.59 | $282K |
| Jan 26, 26 | William John SiboldPresident and CEO | SELL | 1.6K | $492.42 | $777K |
| Jan 26, 26 | Rebecca TaubDirector | SELL | 647 | $492.42 | $319K |
| Jan 20, 26 | Shannon T KelleyGeneral Counsel | SELL | 429 | $501.40 | $215K |
| Jan 20, 26 | Rebecca TaubDirector | SELL | 2.2K | $490.77 | $1.1M |
| Jan 9, 26 | Paul A FriedmanDirector | SELL | 2.5K | $551.24 | $1.3M |
| Jan 9, 26 | Rebecca TaubDirector | SELL | 2.0K | $551.24 | $1.1M |
| Dec 10, 25 | Paul A FriedmanDirector | SELL | 7.2K | $555.39 | $4.0M |
| Dec 10, 25 | Rebecca TaubDirector | SELL | 4.7K | $555.39 | $2.6M |
| Dec 4, 25 | William John SiboldPresident and CEO | SELL | 2.4K | $575.34 | $1.4M |
| Dec 2, 25 | Mardi DierEVP and CFO | SELL | 717 | $596.19 | $412K |
| Nov 21, 25 | Carole HuntsmanChief Commercial Officer | SELL | 894 | $560.62 | $493K |
| Nov 13, 25 | Richard S LevyDirector | SELL | 1.4K | $530.21 | $750K |
| Nov 5, 25 | Kenneth BateDirector | SELL | 3.3K | $490.98 | $1.6M |
| Sep 9, 25 | William John SiboldPresident and CEO | SELL | 7.3K | $445.63 | $3.2M |
| Aug 21, 25 | William John SiboldPresident and CEO | SELL | 6.5K | $401.00 | $2.6M |
| Aug 20, 25 | Baker Bros. Advisors (gp) LlcDirector | BUY | 13.5K | $392.24 | $5.2M |
| Aug 18, 25 | Felix BakerDirector | BUY | 10.1K | $372.16 | $3.8M |
| Aug 18, 25 | Baker Bros. Advisors (gp) LlcDirector | BUY | 26.7K | $374.43 | $10.0M |
| Aug 18, 25 | Shannon T KelleyGeneral Counsel | SELL | 458 | $376.62 | $164K |
| Aug 15, 25 | Kenneth BateDirector | SELL | 2.6K | $368.56 | $938K |
| Aug 13, 25 | Paul A FriedmanDirector | SELL | 29.0K | $374.38 | $10.8M |
| Aug 12, 25 | Paul A FriedmanDirector | SELL | 8.4K | $359.81 | $3.0M |
| Aug 12, 25 | Rebecca TaubDirector | SELL | 6.7K | $359.71 | $2.4M |
| Aug 11, 25 | Paul A FriedmanDirector | SELL | 2.9K | $351.04 | $1.0M |
| Aug 11, 25 | Rebecca TaubDirector | SELL | 3.0K | $351.02 | $1.0M |
| Jul 18, 25 | Paul A FriedmanDirector | SELL | 1.4K | $350.03 | $490K |
| Jul 18, 25 | Rebecca TaubDirector | SELL | 1.0K | $350.01 | $350K |
| Jul 17, 25 | Paul A FriedmanDirector | SELL | 2.0K | $351.57 | $700K |
| Jul 17, 25 | Rebecca TaubDirector | SELL | 2.1K | $351.50 | $720K |
| Jul 16, 25 | Paul A FriedmanDirector | SELL | 6.9K | $356.62 | $2.4M |
| Jul 16, 25 | Rebecca TaubDirector | SELL | 6.4K | $356.52 | $2.3M |
| Mar 13, 25 | Fred B CravesDirector | SELL | 2.0K | $330.23 | $629K |
| Mar 12, 25 | Fred B CravesDirector | SELL | 2.8K | $334.97 | $914K |
| Mar 10, 25 | Mardi DierSVP and CFO | SELL | 258 | $323.04 | $83K |
| Mar 5, 25 | Robert E. WaltermireSenior VP, Chief Pharma Dev. | SELL | 4.7K | $344.76 | $1.6M |
| Mar 3, 25 | Mardi DierSVP and CFO | SELL | 1.2K | $325.89 | $387K |
| Mar 3, 25 | Carole HuntsmanChief Commercial Officer | SELL | 563 | $335.00 | $189K |
| Mar 3, 25 | Shannon T KelleyGeneral Counsel | SELL | 415 | $335.00 | $139K |
| Feb 28, 25 | Robert E. WaltermireSenior VP, Chief Pharma Dev. | SELL | 1.1K | $341.55 | $359K |
| Feb 27, 25 | Kenneth BateDirector | SELL | 8.5K | $360.07 | $3.0M |
| Feb 27, 25 | James M DalyDirector | SELL | 14.3K | $348.94 | $5.0M |
| Jan 24, 25 | Carole HuntsmanChief Commercial Officer | SELL | 347 | $335.24 | $116K |
| Jan 24, 25 | William John SiboldPresident and CEO | SELL | 1.6K | $335.24 | $531K |
Over the past 12 months, insiders at MADRIGAL PHARMACEUTICALS, INC. filed 54 open-market purchases worth $61.9M and 191 sales worth $159.2M on MDGL, which makes them net sellers over the period. The most recent Form 4 was filed on Mar 6, 26.
The largest recent open-market MDGL insider purchase in our data was $10.0M by Baker Bros. Advisors (gp) Llc, Director, filed on Aug 18, 25.
10 different insiders at MADRIGAL PHARMACEUTICALS, INC. filed open-market SEC Form 4 transactions on MDGL over the last 12 months.
InsiderTape plots every MDGL insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every MADRIGAL PHARMACEUTICALS, INC. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →